Investor Presentaiton
Profitability supported by scalability and efficiency gains enabling.
additional innovation and commercial investments
Gross Profit development, %*
YTD 22/23 Gross Profit negatively impacted by inflationary headwind on input
costs (raw materials, energy, freight, labour)
Cost item
Development, in % of revenue*
1.8%-points
67.7
68.0
-0.5%-points
68.5
68.8
67.2
-68
18/19
19/20
20/21
21/22
YTD 22/23 Long-term
*Atos Medical included in FY 21/22 with eight months of impact. Long-term expectations include Atos Medical
38
29.0
28.7
28.2
30.1
30.8
28-30
Distribution
0.5%-points
4.5
4.7
4.2
4.1
3.9
~4
Admin
-0.4%-points
3.9
3.8
3.9
3.8
3.5
R&D
ए
18/19
19/20 20/21
21/22
YTD Long-
22/23 term
FY 21/22 and YTD 22/23 cost items include impact from the Atos Medical
acquisition, of which DKK 152m and DKK 107m respectively in amortization costs
(included under distribution cost)
ColoplastView entire presentation